Nurse vs. doctor monitoring for HIV prevention pill users
Part of Immune system & allergy, Infections clinical trials.
This trial tests whether nurse-led monitoring is as good as doctor-led monitoring for people taking the daily HIV prevention pill (PrEP). It looks at patient satisfaction, care quality, and cost. If you are on PrEP now, this could mean more flexible follow-up options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were assigned male at birth and are 18 or older.
- You are at risk for HIV and currently taking PrEP.
- You are willing to continue your PrEP care in a hospital.
- You are currently followed by a doctor and do not object to being followed by a nurse instead.
- You have health insurance through French Social Security or State Medical Aid (AME).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach to help men at risk for HIV stay healthy by providing access to PrEP through a mobile app. The goal is to see if the program helps men start and stay on PrEP compared to standard care.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This study helps make HIV PrEP (a daily pill to prevent HIV) more available through your regular general practitioner, instead of only at specialized clinics. You may qualify if you are at risk for HIV and want to start or restart PrEP.
This trial looks at how well a daily HIV-prevention pill (F/TAF) works in people who use drugs. The goal is to understand real-world effectiveness and help support people in staying HIV-negative.
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
Hear when a new Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.